Brain Oligometastasis in NSCLC

Management of Patients With Brain-onset Oligometastatic Non-small-cell Lung Cancer (NSCLC)

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in such disease presentation. We will analyze the impact of different therapeutic strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute

75-80% of NSCLC are diagnosed at the metastatic stage. Among the most frequent sites are brain metastases. The management of patients with exclusive limited brain involvement is not standardized. The question is therefore which therapeutic strategy is optimal in terms of disease control: local treatment of the main tumor and brain versus systemic treatment with chemotherapy and immunotherapy. We will analyze the impact of these 2 strategies on patients treated at Bordeaux University Hospital and the Bergonié Institute.

Inclusion Criteria:

• Consecutive patients managed at Bordeaux University Hospital
• Non-small-cell lung cancer
• Oligometastatic brain cancer (fewer than 5 lesions at diagnosis)
• Patient over 18 years old

Exclusion Criteria:

• Oncogenic addiction EGFR, ALK, ROS1
• Patient with concomitant cancer
• Patient with prior treatment for lung cancer in the year preceding diagnosis at metastatic stage